Ono Pharmaceutical Co. Ltd. and Vanderbilt University have prepared and tested new prodrugs of potassium channel subfamily K member 10 (TREK2; KCNK10) and member 2 (TREK-1; KCNK2) inhibitors potentially useful for the treatment of cancer, pulmonary fibrosis, neurological disorders and more.